Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/05/2875486/0/en/TAR-210-results-show-90-percent-recurrence-free-survival-and-90-percent-complete-response-in-patients-with-high-risk-and-intermediate-risk-non-muscle-invasive-bladder-cancer-respec.html
https://www.globenewswire.com/news-release/2024/05/03/2875260/0/en/TAR-200-monotherapy-shows-greater-than-80-percent-complete-response-rate-in-patients-with-high-risk-non-muscle-invasive-bladder-cancer.html
https://www.investor.jnj.com/files/doc_news/2024/Apr/22/carvykti_cartitude-4_ec-release_final.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761044
https://www.globenewswire.com//news-release/2024/03/06/2841454/0/en/Johnson-Johnson-submits-application-to-the-European-Medicines-Agency-for-DARZALEX-daratumumab-based-quadruplet-therapy-for-the-treatment-of-patients-with-transplant-eligible-newly-.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761342
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761291
https://www.jnj.com/media-center/press-releases/janssen-submits-type-ii-extension-of-indication-application-to-the-european-medicines-agency-seeking-approval-of-rybrevant-amivantamab-in-combination-with-lazertinib-for-the-first-line-treatment-of-patients-with-egfr-mutated-non-small-cell-lung-cancer
https://www.ema.europa.eu/en/documents/overview/talvey-epar-medicine-overview_en.pdf
https://www.ema.europa.eu/en/documents/overview/tecvayli-epar-medicine-overview_en.pdf